Factors that explain differences in abstinence between black and white smokers: A prospective intervention study

Journal of the National Cancer Institute

Volumn 111, Issue 10, 2019, Pages 1078-1087

  Nollen, Nicole L ^a   Mayo, Matthew S ^a   Sanderson Cox, Lisa ^a   Benowitz, Neal L ^b   Tyndale, Rachel F ^c   Ellerbeck, Edward F ^a   Scheuermann, Taneisha S ^a   Ahluwalia, Jasjit S ^d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; VARENICLINE;

ADULT; AGE; ARTICLE; BLACK PERSON; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HOME; HOUSEHOLD INCOME; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEIGHBORHOOD; PATIENT ATTENDANCE; PATIENT COMPLIANCE; PATIENT COUNSELING; PLASMA; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK FACTOR; SEX; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SOCIOECONOMICS; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; AFRICAN AMERICAN; EPIDEMIOLOGY; HEALTH SURVEY; MIDDLE AGED; QUESTIONNAIRE; SELF REPORT; UNITED STATES; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PUBLIC HEALTH SURVEILLANCE; RISK FACTORS; SELF REPORT; SMOKERS; SMOKING CESSATION; SOCIOECONOMIC FACTORS; SURVEYS AND QUESTIONNAIRES; TOBACCO SMOKING; UNITED STATES; YOUNG ADULT;

EID: 85069713282     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djz001     Document Type: Article

References (102)

1. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
2. Jamal A, King BA, Neff LJ, et al. Current cigarette smoking among adults-United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44): 1205-1211.
3. Trinidad DR, Perez-Stable EJ, White MM, et al. A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors. Am J Public Health. 2011;101(4):699-706.
4. Trinidad DR, Perez-Stable EJ, Emery SL, et al. Intermittent and light daily smoking across racial/ethnic groups in the United States. Nicotine Tob Res. 2009;11(2):203-210.
5. US National Cancer Institute. A socioecological approach to addressing tobacco related health disparities. In: National Cancer Institute Tobacco Control Monograph 22. NIH Publication No. 17-CA-8035A. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017.
6. American Cancer Society. Cancer Facts & Figures for African Americans, 2016-2018. Atlanta, GA: American Cancer Society; 2017.
7. Cunningham TJ, Croft JB, Liu Y, et al. Vital signs: racial disparities in agespecific mortality among blacks or African Americans-United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017;66(17):444-456.
8. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4):333-342.
9. Babb S, Malarcher A, Schauer G, et al. Quitting smoking among adults-United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017;65(52): 1457-1464.
10. Cokkinides VE, Halpern MT, Barbeau EM, et al. Racial and ethnic disparities in smoking-cessation interventions: analysis of the 2005 National Health Interview Survey. Am J Prev Med. 2008;34(5):404-412.
11. Davila EP, Zhao W, Byrne M, et al. Correlates of smoking quit attempts: Florida Tobacco Callback Survey, 2007. Tob Induc Dis. 2009;5(1):10.
12. Kahende JW, Malarcher AM, Teplinskaya A, et al. Quit attempt correlates among smokers by race/ethnicity. Int J Environ Res Public Health. 2011;8(10): 3871-3888.
13. Levy DT, Blackman K, Tauras J, et al. Quit attempts and quit rates among menthol and nonmenthol smokers in the United States. Am J Public Health. 2011;101(7):1241-1247.
14. Messer K, Trinidad DR, Al-Delaimy WK, et al. Smoking cessation rates in the United States: a comparison of young adult and older smokers. Am J Public Health. 2008;98(2):317-322.
15. Stahre M, Okuyemi KS, Joseph AM, et al. Racial/ethnic differences in menthol cigarette smoking, population quit ratios and utilization of evidence-based tobacco cessation treatments. Addiction. 2010;105(suppl 1):75-83.
16. US Department of Health and Human Services (USDHHS). Tobacco Use Among U.S. Racial/Ethnic Minority Groups-African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: A Report of the Surgeon General. Atlanta, GA: USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1998.
17. Cropsey KL, Clark CB, Zhang XN, et al. Race and medication adherence moderate cessation outcomes in criminal justice smokers. Am J Prev Med. 2015; 49(3):335-44.
18. Daza P, Cofta-Woerpel L, Mazas C, et al. Racial and ethnic differences in predictors of smoking cessation. Subst Use Misuse. 2006;41(3):317-339.
19. Fu SS, Burgess DJ, Hatsukami DK, et al. Race and nicotine replacement treatment outcomes among low-income smokers. Am J Prev Med. 2008;35(suppl 6):S442-S448.
20. Hymowitz N, Sexton M, Ockene J, et al. Baseline factors associated with smoking cessation and relapse. MRFIT Research Group. Prev Med. 1991;20(5): 590-601.
21. Kendrick JS, Zahniser SC, Miller N, et al. Integrating smoking cessation into routine public prenatal care: The Smoking Cessation in Pregnancy project. Am J Public Health. 1995;85(2):217-222.
22. Murray RP, Connett JE, Buist AS, et al. Experience of black participants in the Lung Health Study smoking cessation intervention program. Nicotine Tob Res. 2001;3(4):375-382.
23. Windsor RA, Lowe JB, Perkins LL, et al. Health education for pregnant smokers: its behavioral impact and cost benefit. Am J Public Health. 1993;83(2): 201-206.
24. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks. A randomized clinical trial. JAMA. 2016;315(4):371-379.
25. Croghan IT, Hurt RD, Ebbert JO, et al. Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States. J Public Health. 2010;18(1):59-68.
26. Cropsey KL, Weaver MF, Eldridge GD, et al. Differential success rates in racial groups: results of a clinical trial of smoking cessation among female prisoners. Nicotine Tob Res. 2009;11(6):690-697.
27. Gariti P, Lynch K, Alterman A, et al. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat. 2009;37(3):247-255.
28. Lando H, Hennrikus D, McCarty M, et al. Predictors of quitting in hospitalized smokers. Nicotine Tob Res. 2003;5(2):215-222.
29. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520.
30. Stevens VJ, Solberg LI, Bailey SR, et al. Assessing trends in tobacco cessation in diverse patient populations. Nicotine Tob Res. 2016;18(3):275-280.
31. West R, Eden Evins A, Benowitz NL, et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction. 2018;113(8):1507-1516.
32. Burgess DJ, van Ryn M, Noorbaloochi S, et al. Smoking cessation among African American and white smokers in the Veterans Affairs health care system. Am J Public Health. 2014;104(S4):S580-S587.
33. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31(3):463-491.
34. Caraballo RS, Giovino GA, Pechacek TF, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA. 1998;280(2):135-139.
35. Gandhi KK, Foulds J, Steinberg MB, et al. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. Int J Clin Pract. 2009;63(3):360-367.
36. Gundersen DA, Delnevo CD, Wackowski O. Exploring the relationship between race/ethnicity, menthol smoking, and cessation, in a nationally representative sample of adults. Prev Med. 2009;49(6):553-557.
37. Perez-Stable EJ, Herrera B, Jacob P 3rd, et al. Nicotine metabolism and intake in black and white smokers. JAMA. 1998;280(2):152-156.
38. Smith SS, Fiore MC, Baker TB. Smoking cessation in smokers who smoke menthol and non-menthol cigarettes. Addiction. 2014;109(12):2107-2117.
39. Al Koudsi N, Ahluwalia JS, Lin SK, et al. A novel CYP2A6 allele (CYP2A635) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. 2009;9(4):274-282.
40. Ho MK, Mwenifumbo JC, Zhao B, et al. A novel CYP2A6 allele, CYP2A623, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics. 2008;18(1):67-75.
41. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;2600(14):70294-70292. 10.1016/S2213
42. Mwenifumbo JC, Al Koudsi N, Ho MK, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat. 2008;29(5):679-688.
43. Mwenifumbo JC, Zhou Q, Benowitz NL, et al. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. 2010;11(2):189-198.
44. Businelle MS, Kendzor DE, Reitzel LR, et al. Mechanisms linking socioeconomic status to smoking cessation: a structural equation modeling approach. Health Psychol. 2010;29(3):262-273.
45. Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding. Tob Control. 2009;18(1):43-46.
46. Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective study of an Australian national sample. Addiction. 2006;101(1):121-127.
47. Siahpush M, Yong HH, Borland R, et al. Smokers with financial stress are more likely to want to quit but less likely to try or succeed: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2009; 104(8):1382-1390.
48. Catley D, Ahluwalia JS, Resnicow K, et al. Depressive symptoms and smoking cessation among inner-city African Americans using the nicotine patch. Nicotine Tob Res. 2003;5(1):61-68.
49. Catley D, Harris KJ, Okuyemi KS, et al. The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res. 2005;7(6):859-870.
50. Borrelli B, Bock B, King T, et al. The impact of depression on smoking cessation in women. Am J Prev Med. 1996;12(5):378-387.
51. Kendzor DE, Businelle MS, Costello TJ, et al. Financial strain and smoking cessation among racially/ethnically diverse smokers. Am J Public Health. 2010;100(4):702-706.
52. Kendzor DE, Businelle MS, Reitzel LR, et al. Everyday discrimination is associated with nicotine dependence among African American, Latino, and white smokers. Nicotine Tob Res. 2014;16(6):633-640.
53. Kendzor DE, Reitzel LR, Mazas CA, et al. Individual-and area-level unemployment influence smoking cessation among African Americans participating in a randomized clinical trial. Soc Sci Med. 2012;74(9):1394-1401.
54. McClave AK, Dube SR, Strine TW, et al. Associations between smoking cessation and anxiety and depression among U.S. adults. Addict Behav. 2009; 34(6-7):491-497.
55. Reitzel LR, Businelle MS, Kendzor DE, et al. Subjective social status predicts long-term smoking abstinence. BMC Public Health 2011;11:135.
56. Reitzel LR, Mazas CA, Cofta-Woerpel L, et al. Subjective social status affects smoking abstinence during acute withdrawal through affective mediators. Addiction. 2010;105(5):928-936.
57. Reitzel LR, Vidrine JI, Businelle MS, et al. Neighborhood perceptions are associated with tobacco dependence among African American smokers. Nicotine Tob Res. 2012;14(7):786-793.
58. Robinson CD, Pickworth WB, Heishman SJ, et al. Black cigarette smokers report more attention to smoking cues than white smokers: implications for smoking cessation. Nicotine Tob Res. 2015;17(8):1022-1028.
59. Williams DR. Race, socioeconomic status, and health. The added effects of racism and discrimination. Ann N Y Acad Sci. 1999;896(1):173-188.
60. Cox LS, Nollen NL, Mayo MS, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst. 2012;104(4):290-298.
61. Fu SS, Sherman SE, Yano EM, et al. Ethnic disparities in the use of nicotine replacement therapy for smoking cessation in an equal access health care system. Am J Health Promot. 2005;20(2):108-116.
62. Lerman C, Schnoll RA, Hawk LW, et al. A randomized placebo-controlled trial to test a genetically-informed biomarker for personalizing treatment for tobacco dependence. Lancet Respir Med. 2015;3(2):131-138.
63. Webb Hooper M, Dietz NA, Wilson JC. Smoking urges during treatment and long-term cessation among low-income African Americans. Ethn Dis. 2017; 27(4):395-402.
64. Cooper RS, Nadkarni GN, Ogedegbe G. Race, ancestry, and reporting in medical journals. JAMA. 2018;320(15):1531-1532.
65. Nollen NL, Cox LS, Yu Q, et al. A clinical trial to examine disparities in quitting between African-American and White adult smokers: design, accrual, and baseline characteristics. Contemp Clin Trials. 2016;47:12-21.
66. Fiore M, Jaen C, Baker T, et al. Treating Tobacco Use and Dependence Clinical Practice Guideline: 2008 Update. Washington, DC: US Department of Health and Human Services; 2008.
67. Dorsey R, Graham G. New HHS data standards for race, ethnicity, sex, primary language, and disability status. JAMA. 2011;306(21):2378-2379.
68. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
69. Steptoe A, Feldman PJ. Neighborhood problems as sources of chronic stress: development of a measure of neighborhood problems, and associations with socioeconomic status and health. Ann Behav Med. 2001;23(3):177-185.
70. Sampson RJ, Raudenbush SW, Earls F. Neighborhoods and violent crime: a multilevel study of collective efficacy. Science. 1997;277(5328):918-924.
71. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey. Hyattsville, MD: US Department of Health and Human Services, CDC; 2012.
72. Fagerstrom K, Russ C, Yu CR, et al. The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012;14(12):1467-1473.
73. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9(3):315-327.
74. Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248:1-17.
75. Cappelleri JC, Bushmakin AG, Baker CL, et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32(5):912-923.
76. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
77. Nollen NL, Cox LS, Nazir N, et al. A pilot clinical trial of varenicline for smoking cessation in black smokers. Nicotine Tob Res. 2011;13(9):868-873.
78. Thompson N, Nazir N, Cox LS, et al. Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. Patient Prefer Adherence. 2011;5:475-482.
79. Cohen S, Williamson G, Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds. The Social Psychology of Health. Newbury Park, CA: Sage; 1988:31-68.
80. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: Validity of a two-item depression screener. Med Care. 2003;41(11): 1284-1292.
81. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10): 1092-1097.
82. Sternthal MJ, Slopen N, Williams DR. Racial disparities in health: how much does stress really matter? Du Bois Rev. 2011;8(1):95-113.
83. Centers for Disease Control and Prevention (CDC). Reactions to race. In: Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, GA: US Department of Health and Human Services, CDC; 2012.
84. Diener E, Emmons R, Larsen RA, et al. The satisfaction with life scale. J Pers Assess. 1985;49(1)71-75.
85. Cook WW, Medley DM. Proposed hostility and pharisaic-virtue scales for the MMPI. J Appl Psychol. 1954;38(6):414-418.
86. Dempsey D, Tutka P, Jacob P, 3rd, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1): 64-72.
87. St Helen G, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1105-1114.
88. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6): 635-643.
89. Benowitz N, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
90. West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100(3):299-303.
91. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
92. Hosmer DW, Jovanovic B, Lemeshow S. Best subsets logistic regression. Biometrics. 1989;45(4):1265-1270.
93. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12):1373-1379.
94. Zhu AZ, Renner CC, Hatsukami DK, et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013;22(4):708-718.
95. Ellerbeck EF, Mahnken JD, Cupertino AP, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med. 2009;150(7):437-446.
96. Heckman BW, Cummings KM, Kasza KA, et al. Effectiveness of switching smoking-cessation medications following relapse. Am J Prev Med. 2017;53(2): e63-e70.
97. Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy [erratum appears in Addiction. 2004;99(2):273]. Addiction. 2004;99(1):83-92.
98. Piper ME, Cook JW, Schlam TR, et al. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res. 2010;12(6):647-657.
99. West R, Evins AE, Benowitz NL, et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction. 2018;113(8):1507-1516.
100. Gallo LC, Matthews KA. Understanding the association between socioeconomic status and physical health: do negative emotions play a role? Psychol Bull. 2003;129(1):10-51.
101. Matthews KA, Gallo LC. Psychological perspectives on pathways linking socioeconomic status and physical health. Annu Rev Psychol. 2011;62(1): 501-530.
102. Lerman C, Schnoll RA, Hawk LW Jr., et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebocontrolled trial. Lancet Respir Med. 2015;3(2):131-138.